SIREC-PoumonNCT07904013
Impact of a Radiologic and Immunologic Signature on Cerebral Efficacy of Treatments in Lung Cancers With Brain Metastasis
StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Correlation between MRI-based radiomic signature and transcriptomic signature of brain metastases
Timeframe: At diagnosis, before treatment initiation
Secondary (1)
Correlation between radiomic signature and cerebral progression free survival (PFS) / correlation between transcriptomic signature and cerebral PFS / correlation between immunoradiomic signature and cerebral PFS
Arms and interventions
Patients with brain metastases from NSCLC
Patients aged 18 years or older with advanced or metastatic non-small cell lung cancer, at least one resected brain metastasis at diagnosis, and an indication for first-line immunotherapy plus chemotherapy
Other: Radiomic analysis; Bulk RNA sequencing
Sites
1 site in 1 country
- CHU de Bordeaux, Hôpital Saint-AndréBordeaux, France